Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.10 -5.4%	$1.69	$0.91 ▼ $6.05	$185.84M	2.1	2.55 million shs	1.78 million shs
GLSI Greenwich LifeSciences	$8.76 -1.6%	$9.58	$8.06 ▼ $18.15	$118.98M	1.69	46,332 shs	91,197 shs
LVTX LAVA Therapeutics	$1.33 +1.1%	$1.29	$0.85 ▼ $2.39	$34.46M	0.48	155,889 shs	4,822 shs
TARA Protara Therapeutics	$2.88 -5.6%	$3.39	$1.60 ▼ $10.48	$117.68M	1.34	771,553 shs	366,876 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	-5.41%	-2.78%	+35.48%	+61.54%	-58.90%
GLSI Greenwich LifeSciences	-1.57%	-4.78%	-10.70%	-17.75%	-46.16%
LVTX LAVA Therapeutics	+1.15%	+2.71%	+3.52%	+2.71%	-28.76%
TARA Protara Therapeutics	-5.57%	-9.15%	-7.99%	-39.11%	+27.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	3.8097 of 5 stars	3.2	2.0	4.2	1.4	2.5	0.6
GLSI Greenwich LifeSciences	1.5281 of 5 stars	3.5	1.0	0.0	0.0	3.3	0.0
LVTX LAVA Therapeutics	1.7237 of 5 stars	3.0	5.0	0.0	0.0	0.0	0.0
TARA Protara Therapeutics	2.0741 of 5 stars	3.6	2.0	0.0	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.31	Hold	$4.70	123.81% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	345.21% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	138.99% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	611.81% Upside

Current Analyst Ratings Breakdown

Latest LVTX, GLSI, TARA, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/16/2025	TARA Protara Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$12.00
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$32.31M	5.44	N/A	N/A	$1.63 per share	1.29
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
LVTX LAVA Therapeutics	$11.98M	2.91	N/A	N/A	$1.06 per share	1.25
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/12/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)

Latest LVTX, GLSI, TARA, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.08	3.08
GLSI Greenwich LifeSciences	N/A	1.91	1.91
LVTX LAVA Therapeutics	N/A	6.73	6.73
TARA Protara Therapeutics	N/A	18.03	18.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
GLSI Greenwich LifeSciences	4.16%
LVTX LAVA Therapeutics	N/A
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	1.90%
GLSI Greenwich LifeSciences	51.67%
LVTX LAVA Therapeutics	9.50%
TARA Protara Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable

LVTX, GLSI, TARA, and EDIT Headlines

Recent News About These Companies

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors

June 23 at 8:17 AM | quiverquant.com

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

June 14, 2025 | marketbeat.com

Analysts Set Expectations for TARA FY2026 Earnings

June 10, 2025 | marketbeat.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE

June 7, 2025 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by Analysts

June 5, 2025 | marketbeat.com

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.com

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

June 3, 2025 | marketbeat.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Toronto Dominion Bank Acquires New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 30, 2025 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones Trading

May 24, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)

May 24, 2025 | marketbeat.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2025 | globenewswire.com

Protara Therapeutics Reports Q1 2025 Financial Results

May 11, 2025 | tipranks.com

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

How Protara Therapeutics Reflects Shifts Among Nasdaq Companies by Market Cap

May 3, 2025 | kalkinemedia.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, GLSI, TARA, and EDIT Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.10 -0.12 (-5.41%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$2.14 +0.04 (+1.90%)

As of 07:14 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Greenwich LifeSciences NASDAQ:GLSI

$8.76 -0.14 (-1.57%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.17 +0.41 (+4.68%)

As of 06/23/2025 07:01 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

LAVA Therapeutics NASDAQ:LVTX

$1.34 +0.03 (+2.29%)

As of 06/23/2025 04:00 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Protara Therapeutics NASDAQ:TARA

$2.88 -0.17 (-5.57%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$2.88 0.00 (-0.14%)

As of 04:05 AM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time